• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The rationality of combining second-generation antiandrogens with 177Lu-PSMA or its alpha-emitting congeners for better and durable results: will this dominate the therapeutic landscape and be an upfront consideration in metastatic castration-resistant prostate cancer in the coming years?

作者信息

Basu Sandip, Parghane Rahul V, Joshi Amit, Prabhash Kumar, Banerjee Sharmila

机构信息

Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe.

Homi Bhabha National Institute, Mumbai, India.

出版信息

Nucl Med Commun. 2018 Dec;39(12):1061-1063. doi: 10.1097/MNM.0000000000000932.

DOI:10.1097/MNM.0000000000000932
PMID:30339554
Abstract
摘要

相似文献

1
The rationality of combining second-generation antiandrogens with 177Lu-PSMA or its alpha-emitting congeners for better and durable results: will this dominate the therapeutic landscape and be an upfront consideration in metastatic castration-resistant prostate cancer in the coming years?将第二代抗雄激素药物与177Lu-PSMA或其发射α粒子的类似物联合使用以获得更好和持久疗效的合理性：这会在未来几年主导治疗格局并成为转移性去势抵抗性前列腺癌的首要考虑因素吗？
Nucl Med Commun. 2018 Dec;39(12):1061-1063. doi: 10.1097/MNM.0000000000000932.
2
Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing Lu-PSMA Therapy.接受镥-PSMA治疗的去势抵抗性转移性前列腺癌患者反应和总生存期的预测因素
J Nucl Med. 2018 Jul;59(7):1033-1034. doi: 10.2967/jnumed.118.209270. Epub 2018 Apr 13.
3
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.225Ac-PSMA-617用于转移性去势抵抗性前列腺癌的PSMA靶向α放射治疗。
J Nucl Med. 2016 Dec;57(12):1941-1944. doi: 10.2967/jnumed.116.178673. Epub 2016 Jul 7.
4
Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.放射性配体疗法联合（177）Lu 标记的前列腺特异性膜抗原配体在转移性去势抵抗性前列腺癌患者的成像和治疗中的应用。
J Urol. 2016 Aug;196(2):382-91. doi: 10.1016/j.juro.2016.02.2969. Epub 2016 Mar 8.
5
PSMA radioligand therapy in prostate cancer: overview, latest advances and remaining challenges.前列腺癌中的PSMA放射性配体疗法：概述、最新进展及尚存挑战
Immunotherapy. 2019 Oct;11(15):1267-1271. doi: 10.2217/imt-2019-0146. Epub 2019 Sep 9.
6
Early Prostate-Specific Antigen Changes and Clinical Outcome After Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer.Lu-PSMA 放射性核素治疗转移性去势抵抗性前列腺癌患者后的早期前列腺特异性抗原变化和临床结局。
J Nucl Med. 2020 Oct;61(10):1476-1483. doi: 10.2967/jnumed.119.240242. Epub 2020 Feb 28.
7
Third-line treatment and Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.三线治疗和 Lu-PSMA 放射性配体疗法治疗转移性去势抵抗性前列腺癌：系统评价。
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):496-508. doi: 10.1007/s00259-017-3895-x. Epub 2017 Dec 16.
8
Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice.镥 177 标记前列腺特异性膜抗原放射性核素肽治疗晚期去势抵抗性前列腺癌的疗效和安全性：常规实践中的疗效和安全性。
Cancer Biother Radiopharm. 2018 Sep;33(7):274-281. doi: 10.1089/cbr.2017.2403. Epub 2018 Jul 10.
9
Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.放射性核素标记前列腺特异性膜抗原配体治疗去势抵抗性前列腺癌患者内脏转移对预测疗效和生存结局的价值：系统评价和荟萃分析。
Clin Nucl Med. 2020 Dec;45(12):935-942. doi: 10.1097/RLU.0000000000003307.
10
Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.Bi-PSMA-617靶向α放射性核素疗法治疗转移性去势抵抗性前列腺癌
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1099-1100. doi: 10.1007/s00259-017-3657-9. Epub 2017 Mar 2.

引用本文的文献

1
From Despair to Hope: First Arabic Experience of Lu-PSMA and Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer.从绝望到希望：卢-PSMA和钍-PSMA治疗转移性去势抵抗性前列腺癌的首例阿拉伯语地区经验
Cancers (Basel). 2024 May 23;16(11):1974. doi: 10.3390/cancers16111974.
2
Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer.镥-前列腺特异性膜抗原疗法用于转移性去势抵抗性前列腺癌
Biomedicines. 2021 Apr 15;9(4):430. doi: 10.3390/biomedicines9040430.